Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · mixedMedium impact
Esc
Red and blue medicine capsules opened over a pile of US dollar bills
Photo: Managed Healthcare Executive

Pharma Tariffs Hit 100% on Drugmakers Without Pricing Deals

Federal Register (US Department of Commerce)2 min read5 sources

Why did the 100% pharma tariff start on September 29?

The 100% US tariff on patented drug imports took effect Tuesday for drugmakers without pricing deals, while 17 large firms including Pfizer (PFE) stay exempt until January 2029 under those deals.

Key numbers

Default tariff on patented drugs100%in force from Sep 29
Deal-exempt large drugmakers170% to Jan 20, 2029; one report says 13 (per [5])
Named zero-tariff countries and regions19for orphan, cell and gene drugs
Rate for EU, Japan, S. Korea, Swiss drugs15%instead of 100%
Rate with approved US factory plan20%rises to 100% in 2030 (per [2])
Drugmakers with a non-exempt drug100+mostly small and mid-sized

What happened

The 100% US tariff on patented drug imports took effect Tuesday for drugmakers without pricing deals, while 17 large firms including Pfizer (PFE) stay exempt until January 2029 under those deals. Rare-disease (orphan) drugs and cell and gene therapies pay no tariff if they come from 19 named countries and regions, including the EU, Japan, India and the UK. Drugs from the EU, Japan, South Korea and Switzerland otherwise face 15%, and firms with a US factory plan pay 20%. More than 100 drugmakers, mostly small and mid-sized, make at least one drug that is not exempt.

Why it matters

The 100% pharma tariff matters because it can raise the cost of imported patented medicines that do not qualify for an exemption. Big drugmakers with pricing deals are shielded, so the burden falls mostly on smaller companies that rely on contract factories abroad. An industry group for smaller drugmakers warned the tariffs could raise costs and slow research, and some firms may close or merge.

Who this affects

Marketmixed
Medium impact
Small drugmakers face more risk than deal-signing large drugmakers.
Companybearish
Medium impact
Drugmakers without pricing deals now face a 100% tariff.
Competitorsbullish
Medium impact
Deal signers keep 0% rates through January 2029; others pay.
Industrybearish
Medium impact
Smaller drugmakers may close or merge, CNN reported.

Drugmakers Without Deals vs Deal Signers, EU-Made Drugs, US Factory Plans

Drugmakers without pricing deals—100%—
17 large drugmakers with pricing deals—0%2029-01-20
EU, Japan, S. Korea, Swiss-made drugs—15%—
Firms with approved US factory plan—20%100% in 2030

As of 2026-09-30

How we got here

  1. Proclamation sets 100% tariff on patented drugs and ingredients, with exemptions.

  2. 17 large drugmakers had signed pricing and US manufacturing deals by this date.

  3. Commerce lists 19 eligible jurisdictions and exempt specialty product types.

  4. Tariff takes effect for all other branded drugmakers.

What to watch

  • Whether Commerce clarifies which drugs and companies qualify; no guidance existed as of Sept 21.Q4 2026
  • Small drugmakers seeking the 20% rate through US manufacturing plans, rising to 100% in 2030.Q4 2026
  • Expiry of the 0% rates for the deal-signing large drugmakers.2029-01-20

Educational content only. Not investment advice.

More briefsAll briefs →